Investors & Partners



Cartesian has been funded since inception by a group of investors that includes Schooner Capital, a Boston-based investment firm founded in 1971. With a significant focus on biotechnology, medical device and healthcare services, Schooner approaches all investments with a long-term perspective, enabling Cartesian to focus on product development. For more information, visit


We welcome strategic collaborations that expand the therapeutic applications of our technology platform for autoimmune diseases and cancer.


Our research has been recognized by over $7 million in competitive grant funding from the National Institutes of Health (NIH) and the Maryland Stem Cell Research Fund (MSCRF). We are grateful to our funding partners for helping to pioneer RNA Cell Therapies.

Contact Us

If you are interested in exploring a partnership with us, please contact us at

Scroll to Top